You just read:

Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer

News provided by

Novartis Pharmaceuticals Corporation

03 Aug, 2016, 07:00 ET